LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

Home・Aandelen Lijst・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Gesloten

28.48 -3.29

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

27.7

Max

29.23

Belangrijke statistieken
By Trading Economics
Inkomsten	43M 13M
Verkoop	29M 107M
EPS	0.25
Winstmarge	12.139
Werknemers	524
EBITDA	16M 8.2M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+123.58% upside

Dividenden
By Dow Jones
Volgende Winsten	6 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	17M 1.5B
Vorige openingsprijs	31.77
Vorige sluitingsprijs	28.48

Immunocore Holdings PLC ADR Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

2 jun 2026, 20:30 UTC

Winsten

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2 jun 2026, 23:58 UTC

Marktinformatie

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2 jun 2026, 23:46 UTC

Marktinformatie

Global Equities Roundup: Market Talk

2 jun 2026, 23:46 UTC

Marktinformatie

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2 jun 2026, 23:41 UTC

Marktinformatie

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2 jun 2026, 23:01 UTC

Acquisities, Fusies, Overnames

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2 jun 2026, 23:01 UTC

Acquisities, Fusies, Overnames

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2 jun 2026, 23:00 UTC

Acquisities, Fusies, Overnames

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2 jun 2026, 22:57 UTC

Marktinformatie

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2 jun 2026, 22:50 UTC

Marktinformatie

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2 jun 2026, 21:07 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

2 jun 2026, 21:07 UTC

Marktinformatie

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2 jun 2026, 21:00 UTC

Winsten

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 jun 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

2 jun 2026, 20:46 UTC

Winsten

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 jun 2026, 20:38 UTC

Winsten

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2 jun 2026, 20:21 UTC

Winsten

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 jun 2026, 20:12 UTC

Winsten

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 jun 2026, 20:05 UTC

Winsten

Palo Alto Networks 3Q Product Rev $594M

2 jun 2026, 20:05 UTC

Winsten

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2 jun 2026, 20:05 UTC

Winsten

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2 jun 2026, 20:05 UTC

Winsten

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2 jun 2026, 20:05 UTC

Winsten

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2 jun 2026, 20:05 UTC

Winsten

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2 jun 2026, 20:05 UTC

Winsten

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2 jun 2026, 20:05 UTC

Winsten

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2 jun 2026, 20:05 UTC

Winsten

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2 jun 2026, 20:05 UTC

Winsten

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2 jun 2026, 20:05 UTC

Winsten

Palo Alto Networks 3Q Adj EPS 85c >PANW

2 jun 2026, 20:05 UTC

Winsten

Palo Alto Networks 3Q Loss $177M >PANW

Peer Vergelijking

Prijswijziging

Immunocore Holdings PLC ADR Prognose

Koersdoel

By TipRanks

123.58% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 65.13 USD 123.58%

Hoogste 100 USD

Laagste 33 USD

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor Immunocore Holdings PLC ADR - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

9 ratings

Buy

Hold

Sell

Gebaseerd op 9 analisten die aandelenratings hebben gegeven aan Immunocore Holdings PLC ADR - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.